Attenuation of haloperidol-induced catalepsy by a 5-HT(2C) receptor antagonist

British Journal of Pharmacology

Volumn 126, Issue 3, 1999, Pages 572-574

  Reavill, C ^a   Kettle, A ^a   Holland, V ^a   Riley, G ^a   Blackburn, T P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5HT(2C) and dopamine D2 receptor antagonists; Catalepsy

Indexed keywords

1 [3 FLUORO 5 (3 PYRIDYL)PHENYLCARBAMOYL] 5 METHOXY 6 TRIFLUOROMETHYLINDOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; HALOPERIDOL; RADIOLIGAND; SB 215505; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; HUMAN; HUMAN CELL; KIDNEY CELL; LIGAND BINDING; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; BINDING, COMPETITIVE; CATALEPSY; CELL LINE; DOPAMINE ANTAGONISTS; FLUOROBENZENES; HALOPERIDOL; HUMANS; INDOLES; MALE; PIPERIDINES; QUINOLINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0033058970     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702350     Document Type: Article

References (13)

1. BALSARA, J.J., JADHAV, J.H. & CHANDOKAR, A.G. (1979). Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacol., 62, 67-69.
2. BLIGH-GLOVER, W., JASKIW, G.E., VRTUNSKI, B., UBOGY, D. & MELTZER, H.Y. (1995). 5-HT2 receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schiz. Res., 15, 153-154.
3. 50) of an enzymatic reaction. Biochem. Pharmacol., 92, 881-894.
4. 2C-induced oral dyskinesia. Neuroscience, 72, 117-128.
5. FOX, S.H., MOSER, B. & BROTCHIE, J.M. (1998). Behavioural effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's Disease. Exp. Neurol., 151, 35-49.
6. KALKMAN, H.O., NEUMANN, V., NOZULAK, J. & TRICKLEBANK, M.D. (1998). Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat. Eur. J. Pharmacol., 343, 201-207.
7. 2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther., 277, 968-981.
8. 2C receptor antagonist. Neuropharmacology, 36, 609-620.
9. 2C/2B receptor antagonist. Br. J. Pharmacol., 111, 797-802.
10. MELTZER, H.Y. (1996). Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br. J. Psychiat., 168, (Suppl. 29), 23-31.
11. 2 pKi values. J. Pharmacol. Exp. Ther., 251, 238-246.
12. POYUROVSKY, M. & WEIZMAN, A. (1997). Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. Int. Clin. Psychopharmacol., 12, 263-268.
13. 2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphinositide hydrolysis. J. Neurochem., 69, 1449-1458.